About NKGen Biotech, Inc. Common Stock
https://www.grafacq.comGraf Acquisition Corp. IV does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or other business combination with one or more businesses. Graf Acquisition Corp. IV was incorporated in 2021 and is based in The Woodlands, Texas.
CEO
Paul Y. Song
Compensation Summary
(Year )
Total Compensation (Unknown At The Moment)
Industry Biotechnology
Sector Healthcare
Went public October 2, 2023
Method of going public SPAC
Full time employees 63
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0
Institutional Ownership
Summary
% Of Shares Owned 2.23%
Total Number Of Holders 2
Showing Top 2 of 2
Market Cap $7.46 M
52w High $0.91
52w Low $0.00
P/E -0.04
Volume 200
Outstanding Shares 124.38M
About NKGen Biotech, Inc. Common Stock
https://www.grafacq.comGraf Acquisition Corp. IV does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or other business combination with one or more businesses. Graf Acquisition Corp. IV was incorporated in 2021 and is based in The Woodlands, Texas.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q4-2024 | $652K ▲ | $5.43M ▼ | $-29.41M ▼ | -4.51K% ▼ | $-0.84 ▼ | $-15.27M ▼ |
| Q3-2024 | $0 | $6.79M ▼ | $6.6M ▲ | 0% | $0.22 ▲ | $7.4M ▲ |
| Q2-2024 | $0 | $7.46M ▲ | $-16.09M ▼ | 0% | $-0.67 ▼ | $-15.12M ▼ |
| Q1-2024 | $0 | $7.29M ▼ | $-5.38M ▲ | 0% | $-0.25 ▲ | $-3.99M ▲ |
| Q4-2023 | $0 | $9.13M | $-33.61M | 0% | $-1.54 | $-32.86M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q4-2024 | $0 ▼ | $24K ▼ | $0 ▼ | $0 ▲ |
| Q3-2024 | $8K ▼ | $14.99M ▼ | $62.05M ▼ | $-47.05M ▲ |
| Q2-2024 | $79K ▲ | $15.65M ▼ | $85.36M ▲ | $-69.72M ▼ |
| Q1-2024 | $34K ▲ | $16.32M ▼ | $71.37M ▼ | $-55.05M ▲ |
| Q4-2023 | $26K | $16.48M | $75.17M | $-58.69M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q4-2024 | $-29.41M ▼ | $-6.95M ▼ | $-16K ▲ | $6.97M ▲ | $1.74M ▲ | $-6.94M ▼ |
| Q3-2024 | $6.6M ▲ | $-3.9M ▲ | $-17K ▼ | $3.82M ▼ | $-92K ▼ | $-3.91M ▲ |
| Q2-2024 | $-16.09M ▼ | $-6M ▼ | $-15K ▼ | $6.06M ▲ | $45K ▲ | $-6M ▼ |
| Q1-2024 | $-5.38M ▲ | $-4.03M ▲ | $35K ▲ | $4.01M ▲ | $8K ▲ | $-4.03M ▲ |
| Q4-2023 | $-33.61M | $-6.94M | $-18K | $-1.8M | $-8.76M | $-6.96M |
CEO
Paul Y. Song
Compensation Summary
(Year )
Total Compensation (Unknown At The Moment)
Industry Biotechnology
Sector Healthcare
Went public October 2, 2023
Method of going public SPAC
Full time employees 63
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0
Institutional Ownership
Summary
% Of Shares Owned 2.23%
Total Number Of Holders 2
Showing Top 2 of 2